On September 23, Dezhan Healthcare (000813.SZ) stated at an investor relations event that in addition to 'Ale' and 'Nile', the company will further explore the potential of its existing products. Based on current policies and market conditions, the company will select products with market potential for production resumption, such as Warfarin Sodium Tablets, Quetiapine Hydrochloride Tablets, etc., to enrich the company's sales pipeline of chemical drug products. Furthermore, accelerate the early conversion of some R&D projects into revenue, advance the trial production of Simvastatin microparticles and recombinant human collagen raw materials as soon as possible. In addition, the company currently has ample cash reserves and plans to increase the product pipeline with market potential and development space through mergers and acquisitions of target companies, empowering the added key product pipelines rapidly, accelerating market sales growth, and achieving synergistic growth of the company's products and performance.